
Aaron Mammoser, MD
Fax: (833) 605-2563
Business hours
Monday | 8:00am to 4:30pm |
Tuesday | 8:00am to 4:30pm |
Wednesday | 8:00am to 4:30pm |
Thursday | 8:00am to 4:30pm |
Friday | 8:00am to 4:30pm |
Saturday | - |
Sunday | - |
About us
Aaron Mammoser, MD, MS, is a Neuro-Oncologist specializing in the comprehensive care of people with primary tumors of the brain and spine, CNS lymphoma, brain and spine metastases, leptomeningeal dissemination of cancer (LMD). He also manages patients with neurologic complications of cancer, including headaches, seizures, neuropathy, and other complications from both the diagnosis itself and the subsequent treatment. Dr. Mammoser is a board-certified Neurologist, having completed his internship and residency at the University of Michigan. Following residency, he completed a fellowship in Neuro-Oncology at MD Anderson Cancer Center in Houston, TX. During fellowship, he had the privilege of training under multiple faculty that are currently leading some of the most prestigious Neuro-Oncology programs in the country. This invaluable experience afforded the opportunity during training to experience different perspectives of multiple thought leaders in the Neuro-Oncology field and their different approaches to addressing similar challenges in these complicated patients. After fellowship, he returned to the University of Michigan and practiced out of the University of Michigan Comprehensive Cancer Center for 5 ½ years. During his time on faculty, he received a MS in Clinical Research Design and Statistical Analysis through the University of Michigan School of Public Health. During his time at Michigan, he was involved in numerous clinical trials and other clinical research projects. He served as the PI or Co-I on many industry-sponsored, cooperative group, and investigator initiated Neuro-Oncology clinical trials. In 2016 he joined the LSU Neurosurgery Department of LSU Healthcare in New Orleans as an associate professor and held the prestigious Kelsey Bradly Favrot endowed chair in Neuro-Oncology. Tasked with developing a Brain Tumor Program, LSU was the first, and at times only, brain tumor program in the state of Louisiana to offer a robust portfolio of clinical trials for people with primary brain tumors and brain metastases, providing patients in Louisiana and the Gulf South region cutting edge Neuro-Oncology care. Dr. Mammoser joined the Piedmont Brain Tumor Center in April 2023. He brings with him a wealth of clinical experience, having been in clinic practice for 19+ years, over 15 years of which has been dedicated to brain tumor patients. He is a member of the American Society of Clinical Oncology and the Society for Neuro-Oncology and has served on numerous national committees for both ASCO and SNO. He has extensive experience in clinical research, having been the PI of over 16 clinical studies for people with brain tumors of all types, and maintains a special interest in clinical trials for treatment of primary and metastatic brain tumor and spine tumors. Instilled in him during training, and refined through years of practice, Dr. Mammoser prides himself on helping people maintain their quality of life and mitigate short and long-term effects of their diagnosis and its subsequent treatment while continuing to provide state of the art care.
Schedule an Appointment Today!
Languages | English |
Tags | acoustic neuroma, adjuvant chemotherapy, anaplastic astrocytoma, anaplastic meningioma, anaplastic mixed glioma, anaplastic oligoastrocytoma, astrocytic cancer, astrocytoma tumors, benign neoplasm of brain, benign schwannoma, biological targeted therapy, brain cancer chemotherapy, brain cancer genomics, brain metastases, brain neoplasms, brain tumor bleeding, cancer, cancer chemotherapy, cancer during pregnancy, cancer genomics, cancer immunotherapy, cancer related cognitive disorder, cellular schwannoma, central nervous system germ cell tumors, central nervous system malignancy, central nervous system sarcoma, cerebellar tumor, chemoradiation, choroid plexus tumor, clinical trials, clivus chondroma, cns lymphoma, craniopharyngioma, diffuse intrinsic pontine glioma (dipg), ependymoma, facial nerve schwannoma, facial nerve tumor, ganglioma, ganglioneurocytoma, germ cell tumor, germinoma, glioblastoma multiforme, glioma, hemangioblastoma, hemangiopericytoma, intraocular lymphoma, intraventricular tumor, lumbar puncture, lymphoma, lymphoma genomics, malignant neoplasm of brain stem, malignant neoplasm of cerebellum, malignant neoplasm of frontal lobe, malignant neoplasm of the spinal cord, malignant schwannoma, medulloblastoma, meningioma, metastatic brain cancer, neoplasm of brain stem, neuroblastoma, neurofibromatosis, neuronal glial tumors, neuropathy, olfactory neuroblastoma, oligodendroglioma, optic nerve glioma, optic nerve tumor, optic pathway glioma, orbital tumors, palliative care for cancer symptoms, palliative care for symptom management, palliative care for treatment side effects, paraneoplastic polyneuropathy, personal history of malignant neoplasm of brain, pilocytic astrocytoma, pineal tumor, pineoblastoma, pituitary tumor, pleomorphic xanthoastrocytomas, primary brain tumor, prolactinoma, radiation toxicity, skull base tumor, spinal cord compression, spinal cord tumors, spine mets, spine tumor, spongioblastoma, tectal glioma, temporal tumor, vascular brain tumors, von hippel lindau disease |